The word dementia describes a group of symptoms including memory loss, confusion, mood changes and difficulty with day-to-day tasks.. There are a number of different types of dementia, including Alzheimer’s disease, vascular dementia, dementia with …

Amyloid is a protein which builds up in the brain in Alzheimer’s disease. The discovery of amyloid in Alzheimer’s disease was made possible by scientists who worked with families who had a strong family history of dementia in their 40s and 50s going back generations.

Jun 10, 2022 · PET scans detect specific molecules in the brain. They are more commonly used in research than for diagnosis. By injecting or swallowing safe radioactive dyes which bind to molecules in the brain, the scanner can produce an image of where the target molecules are by detecting the dyes.

Dec 9, 2024 · Brilliantly written and explained in very easy language – thank you. I have just become a carer for a family member with dementia and your forthright and considerate information has been most helpful in understanding what may lay ahead.

Lecanemab (lek-an-e-mab), also called LEQEMBI®, is a drug treatment for Alzheimer’s disease. It is made by the drug company Eisai. It has been licensed for prescription in the UK for people with a confirmed diagnosis of:

Nov 9, 2023 · A new year has arrived. For some, this is the time of year to reflect on both ourselves, and the loved ones we’ve recently spent time with. If you spent time with family and friends, especially those you may not have seen for a while, you might have noticed changes in them that weren’t there before.

In fact, the UK’s ageing population is one of the reasons that more people are being diagnosed with dementia than ever before. However younger people can also develop dementia.

In our body, there are billions of nerve cells which send messages to each other. These messages help us to move, think, and remember. In Alzheimer’s disease and dementia with Lewy bodies, nerve cells become damaged and lose their ability to send messages.

Donanemab is the second drug approved in Great Britain that can slow down Alzheimer’s, after lecanemab.. Donanemab is not yet available on the NHS. In Great Britain it is currently only approved for use by specialist private healthcare providers, and as part of research trials running in some centres in the UK.

Dec 10, 2024 · Let’s take a closer look at what the data show – and what they don’t. What do the new data show? Last year, dementia took the lives of 75,393 people across the UK – that’s about 1,000 more than 2022, and a 1.5% increase.